Ipilimumab, approved by the US Food and Drug Administration for the treatment of metastatic melanoma [27], has been the anti-CTLA-4 mAb most extensively investigated, although the molecular mechanisms underlying its anti-tumor activity have not been fully elucidated. This evidence concerns the gene CTLA4 and metastatic melanoma.